Modality
mAb
MOA
Anti-Aβ
Target
SOS1
Pathway
PI3K/AKT
Thymoma
Development Pipeline
Preclinical
~Jun 2021
→ ~Sep 2022
Phase 1
~Dec 2022
→ ~Mar 2024
Phase 2
Jun 2024
→ Jul 2030
Phase 2Current
NCT04759722
1,387 pts·Thymoma
2024-06→2030-07·Recruiting
1,387 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-224.3y awayPh3 Readout· Thymoma
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2/3
Recruit…
Catalysts
Ph3 Readout
2030-07-22 · 4.3y away
Thymoma
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04759722 | Phase 2/3 | Thymoma | Recruiting | 1387 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 | |
| Zanurapivir | Immunocore | Phase 1 | SOS1 |